(Alliance News) - Futura Medical PLC on Monday announced "positive" home user test results for its Eroxon and prototype Eroxon Intense products. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Futura Medical PLC on Friday said it will pursue major restructuring plans including possible asset sales as it warned of full-year revenue "materially below expectations". Read More
(Alliance News) - Stock prices in Europe opened largely higher, though the FTSE 100 an underperformer, after a busy week of major central bank decisions culminated in an unsurprising hold by the Bank of Japan. Read More
(Alliance News) - Vodafone and IG Group announce acquisitions in Romania and Australia, respectively, while Spire Healthcare reports it is considering its options, including a possible sale of the company. Read More
(Alliance News) - London stocks opened mostly lower on Friday, as investors weighed potential US sanctions on Russia should a ceasefire deal in Ukraine not be reached. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced this week and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Futura Medical PLC on Friday said it expects 2024 revenue and post-tax profit ahead of guidance, but warned of 2025 sales below market expectations, due to slow uptake in the US of its erectile dysfunction treatment. Read More
